Subscribe
19 May 2017Americas

AbbVie Humira patent invalidated by PTAB

AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira (adalimumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).

More on this story

Big Pharma
Got a patent, now where to validate?
22 March 2021   For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Americas
Federal Circuit agrees with PTAB in optical patent appeal
21 January 2021   The US Court of Appeals for the Federal Circuit has affirmed a decision by the US Patent Trial and Appeal Board which centered on the validity of a patent for an ophthalmic illuminator.
Generics
AbbVie and Alvotech settle all US Humira litigation
10 March 2022   AbbVie and Icelandic biosimilar company Alvotech have settled all US litigation over Alvotech’s proposed generic of AbbVie’s blockbuster arthritis treatment Humira (adalimumab).

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug